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Objective: Few studies to date have examined the relationship between hyperhomocysteinemia and peripheral arterial
occlusive disease (PAOD) in young women. In this study we assessed hyperhomocysteinemia as a risk factor for PAOD
in young women. In addition, we evaluated the effect of joint exposure to hyperhomocysteinemia and traditional risk
factors.
Methods: Two hundred twenty women, ages 18 to 49 years, with PAOD and 629 healthy women (control group) from a
population-based case-control study filled out the same structured questionnaire and donated venous blood samples for
determination of plasma homocysteine levels. Hyperhomocysteinemia was defined as nonfasting total plasma homocys-
teine level above the 90th percentile of the control range.
Results: Young women with hyperhomocysteinemia had a 2.5-fold (95% confidence interval [CI], 1.7-3.9) increased risk
for PAOD. When presence of hyperhomocysteinemia was combined with presence of a traditional risk factor, relative risk
strongly increased in smokers (odds ratio [OR], 18.9; 95% CI, 8.3-42.9) and in women with hypertension (OR, 10.3;
95% CI, 5.4-19.8), hypercholesterolemia (OR, 8.5; 95% CI, 4.2-17.1), and diabetes (OR, 8.9; 95% CI, 1.7-46.9).
Conclusions: Hyperhomocysteinemia is a risk factor for PAOD in young women. There is a strong synergistic effect
between hyperhomocysteinemia and all traditional vascular risk factors. Our findings may have implications for risk
management in these young women. (J Vasc Surg 2003;38:772-8.)
Homocysteine is a sulfur-containing amino acid pro-
duced by demethylation of methionine. In human plasma,
homocysteine exists in various fractions. Total plasma ho-
mocysteine is the sum of protein-bound, free-oxidized, and
reduced species of homocysteine in plasma, and is usually
about 5 to 15 mol/L in healthy persons. Hyperhomocys-
teinemia is recognized when total plasma homocysteine
levels are above 15 mol/L.1
Case-control studies have provided convincing and
consistent evidence that hyperhomocysteinemia is a risk
factor for peripheral arterial occlusive disease (PAOD) in
men.2-5 Elevated levels of total plasma homocysteine have
been linked to oxidative damage of the vascular endothe-
lium, proliferation of vascular smooth muscle cells, and
lipid peroxidation, all or which accelerate the process of
atherosclerosis.6
PAOD is a disease of advanced age that affects predom-
inantly men and older women.7,8 In general, it less fre-
quently affects young women. The Framingham study re-
ported a PAOD biennial incidence rate of 3 per 1000
women at risk at ages 30 to 44 years.9 Hormonal protection
against atherosclerotic disease in premenopausal women is
cited as the major reason for this discrepancy.10 Most
studies in young women concluded that those in whom
PAOD develops at an early age have a stronger prevalence
of conventional cardiovascular risk factors.11,12
In most studies of hyperhomocysteinemia as a risk
factor for PAOD, young women formed only a small part of
the study population or were not included at all. Limited
sample sizes made it difficult to evaluate the association in
women in general and in young women in particular. This
concerns the strength of the relationship, the possible
modifying role of established cardiovascular risk factors,
and the effect of joint exposure to hyperhomocysteinemia
and traditional risk factors in young women.12-14
In this study in young women in The Netherlands, we
assessed hyperhomocysteinemia as a risk factor for PAOD.
In addition, we assessed the effect of joint exposure to
hyperhomocysteinemia and traditional risk factors in young
women.
PATIENTS AND METHODS
Patients and control women. Data were obtained
from the Risk of Arterial Thrombosis in Relation to Oral
Contraceptives study, a multicenter population-based case-
control study in The Netherlands of the association be-
tween oral contraceptive use and PAOD.15 Patients were
identified by the Hospital Registration System, and were
women aged 18 to 49 years with no history of cardiovas-
cular disease, who had been consecutively admitted with
first symptoms of intermittent claudication to a collaborat-
ing hospital between January 1990 and December 1999.
PAOD was diagnosed when patients had typical symptoms
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of intermittent claudication, that is, cramping pain of the
calves or buttocks during exercise, and ankle-brachial index
(ABI) at rest less than 0.90, with a decrease of more than
20% after exercise. Furthermore, all patients underwent
intra-arterial angiography for evaluation of chronic lower
extremity ischemia. Only patients with an atherosclerotic
lesion and as a consequence a luminal diameter reduction of
more than 50% were included for analysis.16
Control women were drawn from random population
samples, recruited by random digit dialing. This method
resulted in selection of control women who were approxi-
mately (within 5 years) the same age as the patients and
who lived in the service areas of the participating hospi-
tals.17 Control women had no history of intermittent clau-
dication. Twelve hundred fifty-nine eligible women were
reached by random digit dialing. Of these 1259 control
subjects, 220 (17%) refused to participate, because of no
interest (81%) or lack of time (19%). Thus a questionnaire
was sent to 1039 control subjects who were eligible and
free of previous cardiovascular disease; 925 questionnaires
(73%) were returned. To achieve optimal participation in
the patient and control groups, we first submitted the
questionnaires; if the questionnaires were not returned,
one telephone call was made to ask why.
There were two phases of data collection. In the first
phase, 270 patients and 925 control subjects filled out a
structured questionnaire concerning classic cardiovascular
risk factors. In the second phase of the study, from June
1998 to May 2000, they were seen again, blood samples
were drawn, and blood pressure was measured. In total,
220 patients and 629 healthy control subjects participated
and were included in the data analysis.
All women gave informed consent, and the study was
approved by the ethics committees of the participating
hospitals.
Risk factor assessment. Patients and control subjects
filled out the same structured questionnaire, which com-
prised questions on demographic characteristics, medica-
tion use, and cardiovascular risk factors including smoking
history; body mass index (BMI); history of hypertension,
diabetes mellitus, or hypercholesterolemia; and family his-
tory of cardiovascular disease. Blood pressure was measured
semi-automatically (OmronM1; OMRON Healthcare
GmbH, Hamburg, Germany) by a physician at one point in
time. Blood samples were obtained immediately after the
examination with the subject sitting. Nonfasting blood
samples were drawn from the antecubital vein in 5 mL
Monovette tubes for determination of homocysteine con-
centration. Withdrawal on acidic citrate is a good alterna-
tive for blood tubes on crushed ice when screening patients
in epidemiologic field studies, because total homocysteine
concentrations remain stable for 6 hours.17 Within 6 hours
the Stabilyte blood sample was centrifuged at 2000 rpm for
10 to 15 minutes, and the plasma was separated and stored
at 80°C until analysis.
We categorized smokers as current, former, or never.
BMI was calculated as body weight (kg) over height
squared (m2). Obesity was defined as BMI 27.3 kg/m2 or
greater. Socioeconomic status was defined as the highest
level of education attended by the participant: primary
school, secondary school, or higher education or university.
A positive history of diabetes mellitus was defined as need
for glucose-lowering medication or (nonfasting) serum
glucose concentration 11.0 mmol/L or greater.18 A posi-
tive history of hypercholesterolemia was defined as need for
cholesterol- lowering medication or serum cholesterol con-
centration 5.0 mmol/L or greater.19
This definition is based on the consensus text for lipid-
lowering therapy (the Third Consensus, “Cholesterol,”
published in 1998).20 A positive history of hypertension
was defined as need for antihypertensive drugs or systolic
blood pressure 160 mm Hg or greater or diastolic blood
pressure 95 mm Hg or greater. A positive family history of
cardiovascular disease was defined as occurrence of cardio-
vascular disease (myocardial infarction, stroke, PAOD) be-
fore 60 years of age in one or both parents.
Determination of plasma homocysteine concentra-
tion. Analysis of plasma total homocysteine levels was
performed independent of knowledge of case-control sta-
tus with high-pressure liquid chromatography. This high-
pressure liquid chromatography sodium borohydride/
monobromobimane (NaBH4/mBrB) method used
NaBH4 for reduction and mBrB for derivation, essentially
the method of Fiskerstrand et al,21 with cysteamine as
external standard. A programmable sample processor (Gil-
son model 232 BIO, Dilutor 401) was used for automated
homocysteine reduction, derivation, and sample injection.
After equilibration with 30 mmol/L of ammonium nitrate,
40 mmol/L of ammonium formate, and 4 mmol/L of
tetra-N-butylammonium hydrogen sulphate (pH 3.2), the
thiol derivatives were eluted from the column (Supelcosil
LC-18, 15 cm, 4.6 mm, 3 m) with a 0% to 10.5%
acetonitrile gradient in 11 minutes, with flow rate 1 mL/
min. Values for plasma total homocysteine (expressed as
homocysteine concentration in mol/L) included the sum
of free and bound forms of homocysteine, homocystine,
and homocysteine-cysteine mixed disulphide.22
Hyperhomocysteinemia was defined as nonfasting
plasma total homocysteine values exceeding the 90th per-
centile of the control group (16.1 mol/L).5
Statistical analysis. Means or proportions of cardio-
vascular risk factors were calculated for patients and control
subjects. We calculated odds ratios (OR) as estimates of
relative risk for PAOD in women with hyperhomocysteine-
mia. OR and 95% confidence intervals (CI) were assessed
with unconditional logistic regression models, adjusted for
age. In addition, multivariate adjustment was made for
potential confounding factors, current smoking (yes/no),
hypertension (yes/no), hypercholesterolemia (yes/no), di-
abetes mellitus (yes/no), and obesity (yes/no). We also
conducted subgroup analyses to assess the interactions
between hyperhomocysteinemia and major cardiovascular
risk factors; smoking, diabetes, hypertension, hypercholes-
terolemia, and obesity. Finally, the prevalence of increasing
number of cardiovascular risk factors (atherosclerotic bur-
den) was determined in patients and control subjects. In
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the remainder of the text, all OR are adjusted for age, and
additional adjustments are mentioned.
RESULTS
Characteristics and risk factors in 220 patients with
PAOD and 629 control women are summarized in Table I.
Patients were slightly older, had higher BMI, and were less
educated than control subjects. Also, classic risk factors for
atherosclerosis were all more prevalent in patients. Mean
level of plasma total homocysteine was 13.1 mol/L in the
patient group and 12.2 mol/L in the control group
(difference, 0.9 mol/L; 95% CI, 0.3-1.4). Twenty-two
percent of patients had plasma homocysteine concentra-
tions above the 90th percentile of the control range (16
mol/L). Levels of plasma total homocysteine were asso-
ciated with increasing age in both patients and control
subjects. No association was found for homocysteine with
other classic cardiovascular risk factors.
The risk for PAOD was increased in young women with
hyperhomocysteinemia (OR, 2.5; 95% CI, 1.7-3.9). After
adjustment for presence of traditional risk factors, OR was
reduced only slightly and remained predictive of PAOD.
This relative risk was comparable with risk estimates of the
traditional risk factors of hypertension, hypercholesterol-
emia, and obesity, but was lower than the relative risks of
smoking and diabetes mellitus (Table II).
The effects of joint exposure to hyperhomocysteinemia
and conventional risk factors in young women are pre-
sented in Table III. Among patients without hyperhomo-
cysteinemia, all traditional cardiovascular risk factors clearly
Table II. Odds ratios for peripheral arterial occlusive disease in relation to various risk factors
Patients
(n  220)
Control subjects
(n  629) Age-adjusted
Multivariate
adjusted†
n % n % OR* 95% CI OR 95% CI
Hyperhomocysteinemia 48 22 61 10 2.5 1.7-3.9 2.1 1.3-3.2
Diabetes mellitus 29 14 7 1 14.1 6.0-32.9 12.1 4.9-30.5
Smoking 201 91 425 68 9.9 4.6-17.3 8.7 4.5-17.1
Hypertension 125 59 146 23 4.2 3.0-5.8 3.9 2.7-5.7
Hypercholesterolemia 187 87 384 61 3.5 2.2-5.4 3.0 1.9-4.7
Obesity 70 32 144 23 1.5 1.1-2.2 1.4 1.0-2.1
All variables differed significantly between both groups (P  .05).
*Odds ratio (OR) relative to women without risk factor.
†Adjusted for age, current smoking (yes/no), hypertension (yes/no), hypercholesterolemia (yes/no), diabetes mellitus (yes/no), and obesity (yes/no).
Table I. Characteristics of patients and control subjects*
Patients
(n  220)
Control group
(n  629)
Age (y) 48.0 (7.0) 44.8 (8.3)
Body mass index (kg/m2) 26.2 (5.8) 24.8 (4.2)
Education
Primary school or less 48 (23%) 53 (9%)
Secondary school 147 (69%) 420 (67%)
Higher education or university 17 (8%) 152 (24%)
Cigarette smoking
Current 127 (60%) 213 (34%)
Former 74 (35%) 212 (34%)
Never 10 (5%) 204 (32%)
Systolic blood pressure (mm Hg) 141.4 (23.1) 129.4 (19.3)
Diastolic blood pressure (mm Hg) 84.5 (12.0) 82.1 (11.3)
Hypertension† 125 (59%) 146 (23%)
Cholesterol (mmol/L) 5.7 (1.4) 5.4 (1.1)
Hypercholesterolemia‡ 187 (87%) 384 (61%)
Glucose (mmol/L) 6.5 (4.3) 4.1 (1.4)
Diabetes mellitus¶ 29 (14%) 7 (1%)
Plasma total homocysteine (mol/L) 13.1 (4.8) 12.2 (3.4)
Hyperhomocysteinemia

48 (22%) 61 (10%)
Family history of cardiovascular disease 129 (71%) 232 (38%)
*Data are mean (SD) unless otherwise indicated.
†Defined as use of antihypertensive drugs or systolic blood pressure 160 mm Hg or diastolic blood pressure 90 mm Hg.
‡Defined as use of lipid-lowering drugs or cholesterol plasma concentration 5.0 mmol/L.
¶Defined as use of blood glucose–lowering medication or nonfasting glucose plasma concentration 11.0 mmol/L.

Defined as plasma total homocysteine levels exceeding the 90th percentile of control range (16 mol/L).
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increased the risk. When combined with presence of hyper-
homocysteinemia, the risks, relative to those with neither
risk factors, were high among smokers (OR, 19) and pa-
tients with hypertension (OR, 10), hypercholesterolemia
(OR, 9), or diabetes (OR, 9).
Distribution of atherosclerotic burden in young
women with PAOD is presented in Table IV, and demon-
strates the extensive risk profile for these patients. More
than half of the patients (58%) were exposed to at least three
vascular risk factors.
DISCUSSION
Women with plasma total homocysteine levels exceed-
ing the 90th percentile of the control distribution had a
twofold increased risk for PAOD. The results of our study
indicate that hyperhomocysteinemia is a risk factor for
PAOD in young women.
Joint exposure to hyperhomocysteinemia and tradi-
tional cardiovascular risk factors in young women resulted
in further increased risk estimates. The strength of the
association between hyperhomocysteinemia and peripheral
arterial occlusive disease was not significantly influenced by
level of anatomic obstruction. All young female patients
had extensive risk profiles. The increased risk in young
women with hyperhomocysteinemia and the synergistic
effect of hyperhomocysteinemia in combination with other
vascular risk factors may have implications for risk manage-
ment in these patients.
The prevalence of PAOD in free living populations is
difficult to determine and may be profoundly influenced by
the criteria used to define abnormalities in arterial blood
flow in the legs and by the sensitivity and specificity of the
diagnostic methods used. Angiography is the most accurate
method for diagnosing PAOD.7 However, because it is
invasive, it is not feasible for use in large studies. For many
years the standardized questionnaire developed by Rose et
al23 was used to define presence or absence of intermittent
claudication, the symptomatic stage of disease. The ABI is
now the most common method of diagnosis used in epide-
miologic studies. Criqui et al8 analyzed prevalence rates of
PAOD according to various diagnostic methods. PAOD
defined as presence of intermittent claudication, based on
the Rose questionnaire, underestimated the prevalence of
flow-limiting PAOD. On the basis of ABI, PAOD was two
to seven times more common than history of intermittent
claudication would suggest. In the Rotterdam study, Mei-
jer et al24 investigated prevalence rates of PAOD in the
elderly (55 years), and found that the prevalence of
PAOD, defined as ABI less than 0.90 in at least one leg, was
19%, and prevalence of intermittent claudication was 2%.
Although PAOD is generally considered a disease of older
men and women, it also occurs in young adults (younger
than 50 years). Hansen et al25 pointed out that adults
younger than 50 years make up 1% to 7% of all patients
Table III. Odds ratios for peripheral arterial occlusive disease in relation to hyperhomocysteinemia according to other
risk factors
No hyperhomocysteinemia Hyperhomocysteinemia
Patients/control
group OR* 95% CI
Patients/control
group OR* 95% CI
Smoking
No 8/195 1 reference 2/9 5.4 1.0-29.4
Yes 157/373 9.6 4.6-20.0 44/52 18.9 8.3-42.9
Hypertension
No 75/438 1 reference 11/44 1.4 0.7-2.9
Yes 92/130 3.6 2.5-5.2 33/16 10.3 5.4-19.8
Hypercholesterolemia
No 17/223 1 reference 11/22 5.7 2.3-14.3
Yes 151/345 4.8 2.8-8.4 36/39 8.5 4.2-17.1
Diabetes
No 141/563 1 reference 38/58 2.5 1.6-4.0
Yes 24/5 19.0 7.0-51.1 5/2 8.9 1.7-46.9
Obesity
No 104/429 1 reference 31/48 2.6 1.5-4.3
Yes 55/132 1.6 1.1-2.3 15/12 4.5 2.0-10.1
All odds ratios differed significantly from reference (P  .05)
*Multivariate adjusted odds ratio (OR) adjusted for age, and all other variables in the table, are relative to reference category. Note: Totals may differ because
of missing data.
Table IV. Distribution of atherosclerotic burden in
young women with peripheral arterial occlusive disease*
No. of vascular
risk factors
Patients Control group
n % n %
1 215 98 558 88
2 207 94 373 60
3 128 58 134 21
4 49 22 36 6
*Cardiovascular risk factors studied were current smoking (yes/no), hyper-
tension (yes/no), hypercholesterolemia (yes/no), diabetes mellitus (yes/
no), and obesity (yes/no).
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treated for lower extremity ischemia. Only the Framingham
study9 analyzed young women separately and found an
age-specific PAOD (defined as presence of intermittent
claudication) biennial incidence rate of 3 per 1000 women
at risk at ages 30 to 44 years.
The relative risk for PAOD in young women with
hyperhomocysteinemia (OR, 2.5; 95% CI, 1.7-3.9) is in
agreement with the results of previous studies that investi-
gated patients with PAOD, which mainly or exclusively
included men.26-30 In 1996 van den Berg et al21 reported a
relative risk of 2.8 (95% CI, 1.1-7.5), in 1997 Cheng et al5
showed a relative risk of 3.7, and in the same year the
European Concerted Action Project yielded a relative risk
of 1.7 (95 CI, 1.0-2.9).27 The mechanism by which hyper-
homocysteinemia may induce vascular damage is still not
fully understood, and theories of homocysteine causing
direct endothelial damage, promoting thrombosis, and
lipid peroxidation have been suggested.28,29 A crucial ques-
tion is whether hyperhomocysteinemia is directly involved
in the pathogenesis of vascular disease or only a marker of
increased risk. Case-control studies are hampered in an-
swering this question, because patients are studied after the
disease has been diagnosed. Therefore prospective inter-
vention studies with homocysteine-lowering medication
are necessary to clarify the importance of homocysteine
concentration in arterial disease.30-32
The twofold increased risk in young women with
PAOD with hyperhomocysteinemia is equivalent to the
relative risk with the traditional risk factors of hypertension,
hypercholesterolemia, and obesity, and is surpassed only by
smoking and diabetes mellitus. These results confirm the
findings of previous studies that pointed out the striking
association between cigarette smoking and PAOD in
young women.10-12 The Framingham study9 identified
smoking as the major risk factor for peripheral arterial
disease in women and showed a synergistic effect with
multiple risk factors. Diabetes mellitus has traditionally
been regarded as an important factor for development of
PAOD, with the occlusive process affecting the most distal
vessels.33
No previous studies have evaluated such a large number
of young female patients. The number of patients included
was sufficient to allow examination of the effect of joint
exposure to hyperhomocysteinemia and traditional cardio-
vascular risk factors. We found a strong interaction between
hyperhomocysteinemia and the other risk factors, much
more pronounced than the effect of synergism between two
conventional cardiovascular risk factors in a general popu-
lation. The most impressive joint effect was seen in women
with hyperhomocysteinemia who smoked. This resulted in
a high, almost 20-fold, increased risk for PAOD. Results of
previous studies investigating this specific relationship con-
cluded that it is conceivable that homocysteine may in-
crease smoking-related platelet and clotting effects or exert
a toxic effect on the endothelium.34 Furthermore, smoking
lowered levels of vitamin B6 and folate, which partly ex-
plains the increased levels of homocysteine in smokers.35
The combination of hyperhomocysteinemia and hyperten-
sion resulted in a 10-fold increased risk. Although the exact
mechanism is unknown, the association between hyperho-
mocysteinemia and impaired renal function is extensively
described and has been the subject of scientific debate in
the medical literature for years.36 Impaired renal function
causes an increase in the half-life of total homocysteine, as a
consequence of reduced renal clearance. This could also
explain the increased risk in women with diabetes and
hyperhomocysteinemia.37 Results of previous studies indi-
cate that patients with diabetes tend to have high homo-
cysteine levels as a consequence of nephropathy. The joint
effects of hyperhomocysteinemia and hypercholesterolemia
and of hyperhomocysteinemia and obesity found in our
study have not been described before. Biochemical expla-
nations for these associations have not been identified.38
The results of our study indicated that young women
with PAOD are marked by an extensive risk profile com-
pared with healthy control women of the same age; 58% of
all patients had at least three traditional risk factors, and
22% of all patients had at least four traditional risk factors.
The extensive risk profile for young female patients, com-
bined with the synergistic effect between hyperhomocys-
teinemia and traditional risk factors, may have implications
for risk management in these patients. Loncar et al39 con-
cluded that total plasma homocysteine concentration may
not be suitable as a screening test for PAOD in the general
population, but serves as a monitoring marker in certain
risk groups. On the basis of our results, we believe that
measurement of homocysteine concentration should be
considered a monitoring marker in young women with
PAOD with one or more traditional cardiovascular risk
factors, to trace additional risk factors. In young patients
with extended risk profiles, control and reduction of risk
factors are particularly important.
This study is the first large case-control study of the
association between hyperhomocysteinemia and PAOD in
young women. One potential limitation of this study is that
we measured nonfasting homocysteine levels. However, stud-
ies on the influence of food intake on homocysteine concen-
tration provide convincing data that plasma total homocys-
teine level is not influenced much by breakfast.40
Furthermore, the effect of potential bias incurred by nonfast-
ing measurements on risk estimates is minimized because of
the case-control design, which implies that both patients and
control subjects were affected equally. In this study, mean
values or nonfasting plasma total homocysteine levels in our
control group, 12.2mol/L, were within the normal range of
fasting homocysteine levels in women in other studies.5,27,34
Another shortcoming of our study is lack of data regarding
renal function in patients and control subjects. Decreased
renal function is accompanied by increased plasma homocys-
teine concentrations. There are two mechanisms by which
atherosclerotic vessel disease could affect renal function in our
patients. The first, and most significant, pathway is hyperho-
mocysteinemia as a consequence of severe renal impairment
caused by focal renal artery stenosis. In our study, PAOD was
diagnosed with intra-arterial angiography. On these angio-
grams we did not see significant focal stenosis of the renal
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arteries; thus homocysteine concentration could not have
been influenced by this mechanism in our patients, or at best
only minimally so. The second pathway consists of elevated
homocysteine levels as a consequence of generalized intrarenal
arteriosclerosis in patients with PAOD. Because we did not
incorporate markers of renal function in our analyses, this
mechanism could have biased our results. Another potential
limitation was that we assessed history of PAOD in healthy
control subjects by using a structured questionnaire and not
with angiography, as in the patient group; therefore we do not
know how many control subjects in fact had asymptomatic
PAOD.
CONCLUSION
Hyperhomocysteinemia is a risk factor for PAOD in
young women. The combination of hyperhomocysteine-
mia and traditional vascular risk factors results in high risk.
The extensive risk profile of young women, combined with
the synergistic effect between hyperhomocysteinemia and
traditional risk factors, may have implications for risk man-
agement in these patients. Measurement of homocysteine
concentration should be considered a monitoring marker,
and control of smoking, diabetes, hypertension, hypercho-
lesterolemia, and obesity may be particularly important in
young women with hyperhomocysteinemia.
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